Evidence map›Paper›PMID 35612826›Full record

ArticleACS infectious diseases2022

Development of a Simple and Effective Lipid-A Antagonist Based on Computational Prediction.

Olivia Slater, Kapur B Dhami, Ganesh Shrestha, Maria Kontoyianni, Michael R Nichols, Alexei V Demchenko

Open access · greenAbstract read
In one paragraph

Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Olivia SlaterDepartment of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, Illinois 62026, United States.
Kapur B DhamiDepartment of Chemistry and Biochemistry, University of Missouri─St. Louis, One University Boulevard, St. Louis, Missouri 63121, United States.
Ganesh ShresthaDepartment of Chemistry and Biochemistry, University of Missouri─St. Louis, One University Boulevard, St. Louis, Missouri 63121, United States.
Maria KontoyianniDepartment of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, Illinois 62026, United States.
Michael R NicholsDepartment of Chemistry and Biochemistry, University of Missouri─St. Louis, One University Boulevard, St. Louis, Missouri 63121, United States.ORCID 0000-0001-5458-218X
Alexei V DemchenkoDepartment of Chemistry and Biochemistry, University of Missouri─St. Louis, One University Boulevard, St. Louis, Missouri 63121, United States.ORCID 0000-0003-3515-212X
University of Missouri–St. Louis · USSouthern Illinois University Edwardsville · US

Funding

Automation of the chemical synthesis of human milk oligosaccharidesR01GM111835 · NIGMS · SAINT LOUIS UNIVERSITY · PI DEMCHENKO, ALEXEI V · 2014 to 2023
$2.5M
NIGMS NIH HHS R01 GM111835
6 · The paper itself

Abstract

Sepsis is a serious medical condition characterized by bacterial infection and a subsequent massive systemic inflammatory response. In an effort to identify compounds that block lipopolysaccharide (LPS)-induced inflammation reported herein is the development of simple Lipid-A analogues that lack a disaccharide core yet still possess potent antagonistic activity against LPS. The structure of the new lead compound was developed based on predictive computational experiments. LPS antagonism by the lead compound was not straightforward, and a biphasic effect was observed suggesting a possibility of more than one binding site. An IC

Indexed as

Lipid ALipopolysaccharidesBinding SitesHumansInflammationToll-Like Receptor 4Lipid ALipopolysaccharidesToll-Like Receptor 4antagonistconjugatesdocking experimentsinflammationlipopolysaccharideToll-like receptors

Identifiers

PMID35612826
PMCPMC9402072
OpenAlexW4281551633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.